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Background: The metabolic syndrome (MS) is termed a cluster of multiple metabolic risk criteria which is positively
correlated with cardiovascular disease and type 2 diabetes mellitus (DM). Yam dioscorins have been reported to
exhibit biological activities, however, little is known their preventive effects on the MS. Therefore, a high-fat (HF) diet
was used to induce Wistar rat obesity and then yam dioscorin (50 mg/kg, dio50) was intervened daily concurrent
HF diet (HF diet + dio50) for five weeks to check the changes of weights of body and tissues, blood pressures, and
impaired glucose tolerances. The in vitro peptic hydrolysates of dioscorin with molecular mass between 3 kDa and
10 kDa and less than 3 kDa were used to determine dipeptidyl peptidase IV (DPP IV) inhibitory activities which DPP
IV inhibitor has been reported to prevent and treat type 2 DM.
Results: There were no significant difference in body weights, feed intakes, feed conversion, and weights of adipose
tissues of obese rats in groups of HF and (HF diet + dio50). However, the systolic blood pressures in obese rats of 2-, 3-
and 4-week dioscorin interventions were showed significantly lower (P < 0.05) compared to the HF group. The dioscorin
intervention (HF+ dio50) was showed significantly different (P < 0.05) and improved the impaired glucose tolerances
compared to HF group in obese rats by the oral glucose tolerance tests. It was also found that the fraction with
different molecular mass of dioscorin peptic hydrolysates (5 mg/ml) showed inhibitory activities against DPP IV using
sitagliptin phosphate as positive controls.
Conclusions: Yam dioscorins exhibit improved MS activities in obese rats which the related mechanisms may need
further investigations.
Keywords: Dioscorin; Dipeptidyl peptidase IV (DPP IV); Metabolic syndrome (MS); Peptic hydrolysates; Systolic blood
pressure; YamBackground
The metabolic syndrome (MS) is termed a cluster
of five multiple metabolic risk criteria, including (1)
abdominal obesity (central obesity), (2) hypertriglyc-
eridemia [fasting triglycerides (TGs) ≥ 150 mg/dl], (3)
low serum high-density lipoprotein cholesterol (HDL ≤
40 mg/dl), (4) elevated blood pressure (systolic ≥
130 mmHg or diastolic ≥ 85 mmHg), and (5) high fasting* Correspondence: sylin@tmu.edu.tw; wchou@tmu.edu.tw
†Equal contributors
3Department of Primary Care Medicine, Taipei Medical University Hospital,
Taipei, Taiwan
2Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei,
Taiwan
Full list of author information is available at the end of the article
© 2015 Shih et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is pblood glucose (≥110 mg/dl), and an increasing obesity and
sedentary lifestyles relate positively the rising MS world-
wide prevalence (Day 2007; Alberti et al. 2009). A general
diagnosis with three out of above-mentioned five criteria
can recognize as the MS (Day 2007). Insulin resistance
and impaired glucose tolerance are also two important
metabolic risk criteria which may involve in factors for the
MS general diagnosis (Day 2007). The health risks of MS
associated with obesity vary among individuals, but con-
sistently include type 2 diabetes mellitus (type 2 DM),
hypertension, coronary heart disease and cancer (Zimmet
1982; Prentice 2006). The abdominal obesity may play the
central role in MS which is the situation of exceeding vis-
ceral fat deposited in peritoneal cavity, and will initiate in-
flammation and dyslipidemia, increase the blood pressureOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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mal blood glucose. Obesity is blamed as a major contribut-
ing factor in over 0.3 million deaths per year in the
America and related economic costs over US 100 billion
per year (Daniels 2006; Rodgers et al. 2012). In fact, obes-
ity associated with diabetes are considered not only a clin-
ical problem but also a public health issue in many
countries, and 80% of overweight people are also diag-
nosed with type 2 DM which are referred as “the twin epi-
demics” (Smyth and Heron 2005).
Several animal models are established and suitable for
one or more metabolic risk criteria in MS studies (Panchal
and Brown 2011), such as genetic rodent models, including
db/db mice, ob/ob mice, Zucker diabetic fatty rats, and
Otsuka Long-Evans Tokushima fatty (OLETF) rats etc.,
however, such genetic mutations in established rodent ani-
mals are few reported in humans; on the other hand, the
diet-induced rodent models may mimic closely to MS
symptoms in humans, including fructose-induced, sucrose-
induced, and high-fat (HF) diet induced rodent animals
(Panchal and Brown 2011). The HF diets are reported to
induce overweight, obesity, dyslipidemia, insulin resistance,
and high blood pressures in rodent animals (Agulia and
Mandarim-de-Lacerda 2003; Woods et al. 2003; Kobayasi
et al. 2010), and are widely used for MS study (Frigolet
et al. 2013).
The dipeptidyl peptidase IV (DPP IV) is a serine-type
proteinase (EC 3.4.14.5) which metabolizes peptide hor-
mones, such as glucagon-like peptide-1 (GLP-1), an
insulinotropic peptide hormone can stimulate glucose-
dependent insulin secretions (Mentlein 2005; Drucker
2006; Idris and Donnelly 2007). DPP IV inhibitors that
control the glycermia by modulating the GLP-1 levels
are currently developed for type 2 DM treatments
(Smyth and Heron 2005; Idris and Donnelly 2007). DPP
IV cleaves the Pro or Ala at the second position of the
active N-terminal GLP-1(7–37) or GLP-1(7–36) amide
which results in functional inactive GLP-1(9–37) or
GLP-1(9–36) amide (Drucker 2006; Idris and Donnelly
2007). Therefore, researchers attempted to isolate poten-
tial DPP IV inhibitory peptides from protein hydroly-
sates, such as pepsin-pancreatin hydrolysates of sodium
caseinate, skim milk powders and milk protein concen-
trates (Lacroix and Li-Chan 2012), Umamizyme G hydro-
lysates of defatted rice bran (Hatanaka et al. 2012), and
pepsin-treated whey protein (Lacroix and Li-Chan 2013).
Yams are recognized as herbal plants since the tuber
dried slices are widely used as Chinese herbal medicines,
and the fresh tuber has also been a staple food in West
Africa, Southern Asia, and the Caribbean. The tubers of
yam storage protein, dioscorin, account for about 90% of
the extractable water-soluble proteins from different
species as estimated by the immune staining method
(Hou et al. 2000). The yam dioscorin and/or its peptichydrolysates have been reviewed for biological activities
in vitro and/or in vivo (Lu et al. 2012), among which the
antihypertensive activities (Hsu et al. 2002; Lin et al.
2006; Liu et al. 2009a,b; Lin et al. 2014) and antioxidant
activities (Hou et al. 2001; Liu et al. 2006; Han et al.
2013, 2014a,b,c) may involve in MS studies. Therefore, a
HF diet which the fat composition provide 60% of total
calories is used to induce obese rats and then yam dios-
corin is intervened to observe the changes of body
weights, blood pressures, and glucose tolerances. It is
also to test the pepsin hydrolysates of yam dioscorin to
evaluate DPP IV inhibitory activities.
Methods
Materials
DPP IV (lyophilized powder, ≥ 10 units/mg protein, D-
7052), glucose, Gly-Pro p-nitroanilide, pepsin (3460 units/
mg solid, P-6887), and sitagliptin phosphate were pur-
chased from Sigma Chemical Co. (St. Louis, MO). The HF
diet for obesity induction (fat composition provide 60% of
total calories, D12942) was purchased from Research Diets,
Inc. (NJ, USA). The standard mouse/rat chow (fat compos-
ition provide 12.137% of total calories, Prolab® RMH2500,
5P14 Diet; PMI Nutrition International, MO, USA).
HF diets-induced obese rats for MS studies
Male 10-week-old Wistar rats (N = 24) were purchased
from National Laboratory Animal Center (Taipei, Taiwan)
and housed in wire-bottomed stainless steel cages in a
temperature- and humidity-controlled room (at 22°C) with
a 12-h light/dark cycle which had free access to the feeds
and water. All animal experimental procedures were
reviewed and approved by the Institutional Animal Care
and Use Committee, Taipei Medical University (LAC-100-
0038). After acclimation for one week, rats were randomly
divided into three groups (N = 8 for each group), including
a blank group for standard mouse/rat chow and two HF
diet-induced obese groups (one control as HF group and
one dioscorin-intervened group) for 70-days. In the dios-
corin intervened group, yam dioscorin (50 mg/kg, dio50)
was intervened daily concurrent HF diets (HF + dio50)
from day-36 to day-70. The rat weights and feed intakes
were recorded during experiments. The feed conversion is
defined as a ratio of amounts of feed intakes (g) divided by
rat weight gains (g) during experimental periods. Rats were
sacrificed, organs (heart, lung, liver, kidney, and spleen)
and adipose tissues (retroperitoneal fat, mesenteric fat, vis-
ceral fat, and testicle fat) were collected and weighted for
comparisons.
Changes of blood pressures in the dioscorin intervention
of HF diet-induced obese rats
The systolic blood pressure (SBP) and diastolic blood
pressure (DBP) of rats were measured at the end of each
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weeks by using an indirect tail-cuff blood pressure meter
(BP-98A, Softron Co. Ltd. Tokyo, Japan). Distilled water
(0.5 ml) was administered to the rats in the normal diet
group (the blank) and HF group (the control) instead of
dioscorin solutions for comparisons.
Impaired glucose tolerances in the dioscorin
interventions of HF diet-induced obese rats by oral
glucose tolerance tests
Impaired glucose tolerance of HF diet-induced obese
rats were measured by oral glucose tolerance tests
(OGTT) following the previous report (Ito et al. 2001;
Andrikopoulos et al. 2008) with modifications. Rats of
each group at the ends of the 10th-week were fasted for
16 hours and glucose was administered by oral gavage at
1 g/kg body weight. Blood (0.1 ml) was obtained from
the tail vein of rats at 0, 5, 30, 60, 90, and 120 min after
the glucose loads. Plasma glucose were determined by
using RANDOX glucose kit (Randox Laboratories-US,
Ltd. USA). The assay principle is based on the hydrogen
peroxide generation catalyzed by glucose oxidase and
further reacted with phenol and 4-aminophenazone to
produce reddish violet quinoneimine dye with absorb-
ance at 505 nm.
DPP IV inhibitory activities of peptic hydrolysates of yam
dioscorin
The procedure for peptic hydrolysates of yam dioscorin
was following the previous reports (Hsu et al. 2002; Liu
et al. 2006). The hydrolytic ratio (wt/wt) of yam dioscorin
(g) to pepsin (g) was set at 5/1 in 0.1 M KCl buffer (pH 2.0)
with stirring at 4°C for 3 days. After hydrolysis, 1.0 M
Tris–HCl buffer (pH 8.3) was added to pH 7.5 to stop hy-
drolysis. The molecular cut-off centricon or centriprep de-
vice (YM-10, 10 kD; YM-3, 3 kD; Millipore Co., USA) was
used to separate peptic hydrolysates of yam dioscorin into
three portions as followings: higher than 10 kD (peptide >
10 kDa), between 3 to 10 kD (3 kD < peptide < 10 kD), and
less than 3 kDa (peptide < 3kD). The fractions of between 3
to 10 kD (3 kD < peptide < 10 kD) and less than 3 kDa
(peptide < 3kD) were further analyzed by reverse-phase
C18 Spherical HPLC column (10 mm× 250 mm). The mo-
bile phase was mixed in stepwise gradients with solvent A
(deionized water containing 0.1% trifluoroacetic acid) and
solvent B (100% acetonitrile containing 0.1% trifluoroacetic
acid) as followings, 0 to 5 min, 100% to 79% solvent A and
0 to 21% solvent B; 21 min, 75% solvent A and 25% solvent
B; 22 min to 27 min, 60% solvent A and 40% solvent B;
40 min, 0% solvent A and 100% solvent B. Flow rate was
3 ml/min. The detector was set at 220 nm. The latter two
fractions were lyophilized for DPP IV inhibitory assays.
The DPP IV inhibitory activity was assayed according
the previous report (Lacroix and Li-Chan 2013) withmodifications. The DPP IV enzyme powder (≥10 units/mg
protein) was re-dissolved in 1 ml of 100 mM Tris buffer
(pH 8.0) as a stock enzyme solution and a 50-fold dilution
before uses as a working enzyme solution. The substrate,
Gly-Pro p-nitroanilide, was prepared as 4 mM stock solu-
tions. The sitagliptin phosphate, the DPP IV inhibitor
(Drucker et al. 2007) as the positive control, was prepared
as 1 μM stock solutions. Each 50 μl of working DPP IV
enzyme solution and peptic dioscorin fractions was mixed
at 37°C for 10 min, then 50 μl of substrate was added and
adjusted to 200 μl by 100 mM Tris buffer (pH 8.0). The
sitagliptin phosphate was used instead of tested dioscorin
fraction for the control. The 100 mM Tris buffer (pH 8.0)
was used instead of tested dioscorin fraction for the blank.
The absorbance at 405 nm was measured at 60 min
by using an ELISA reader (TECAN Sunrise microplate
reader; Männedorf, Switzerland). The DPP IV inhibition
(%) was calculated as (A405blank-A405sample or control/
A405blank) × 100%.
Statistical analyses
Data were expressed as mean ± SEM in the rat weight
changes and impaired glucose tolerances by OGTT
methods, others were expressed as mean ± SD. Multiple
group comparisons under the same treated time were
performed using one-way analysis of variance (ANOVA)
followed by the post hoc Tukey’s test, and values that
have not been indicated with the same alphabet were
significantly different (P < 0.05). Statistical analysis was
performed using the GraphPad Prism 5.0 software (San
Diego, CA, USA).
Results
Effects of dioscorin interventions on body weights of HF
diet-induced obese rats
At the day 36, the average weight of rats in the group of
normal diet, HF diet, and (HF diet + dio50) was 389.65 ±
22.79 (g), 462.25 ± 11.06 (g), and 459.32 ± 38.94 (g), re-
spectively. At the day 68, the average weight of rats in the
group of normal diet, HF diet, and (HF diet + dio50) was
427.17 ± 18.20 (g), 514.90 ± 13.44 (g), and 509.76 ± 28.54
(g), respectively. Rats fed with the standard chow (the nor-
mal diet) showed lighter average body weights and signifi-
cant difference (P < 0.05) compared to those fed with HF
diets without or with dioscorin interventions during 70-
day experiments (Figure 1A). While, the average weight of
rats in two groups of HF-induced obese rats, namely HF
diet group or with yam dioscorin interventions (HF diet +
dio50) group showed no significant differences (P > 0.05)
at the beginning (day 36) and the ends (day 68) of ex-
periments (Figure 1A). It meant that yam dioscorin inter-
ventions at 50 mg/kg for 5 weeks showed no weight
reduction activity against obese-induced rats at the
present protocol designs. Figure 1B showed the feed















































































































































































Figure 1 Effects of dioscorin interventions (50 mg/kg) on (A) body weights, (B) feed intakes, (C) feed conversion (feed intakes/weight
gains), and(D) weights of organ and fat tissues of high fat-diet induced obese rats. Arrow indicates the dioscorin intervention from day 36
to day 70. Data were expressed as mean ± SEM in the rat weight changes and others were expressed as mean ± SD. Multiple group comparisons
under the same treated time were performed using one-way analysis of variance followed by the post hoc Tukey’s test, and values that have not
been indicated with the same alphabet were significantly different (P < 0.05). HF, a high-fat diet; (HF diet + dio50), yam dioscorin (50 mg/kg,
dio50) was intervened daily concurrent HF diet.
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groups were showed linearly increases, while, rats fed with
the standard chow (the normal diet) showed higher feed
intakes and significant difference (P < 0.05) compared to
those fed with HF diets without or with dioscorin inter-
ventions during 70-day experiments (Figure 1B). Figure 1C
showed the feed conversion rate of three rat groups during
obesity-induced and the whole experimental stages which
was calculated from feed intakes (data in the Figure 1B)
divided by weight gained (data in the Figure 1A). Rats fed
with the standard chow (the normal diet) showed higher
feed conversion rate and significant difference (P < 0.05)
compared to those fed with HF diets without or with dios-
corin interventions during obesity-induced and the whole
experimental stages (Figure 1C). It meant that more of
standard chow (the normal diet) were needed compared
to those of HF diet to gain the same weight. Figure 1D
showed the organ weights of three rat groups. Generally,
rats in the normal diet group showed significant difference
(P < 0.05) and lower weights of adipose tissues (such as
retroperitoneal fat and testicle fat) than those in the HF
diet groups. Other organs except from kidney showed no
significant difference among three groups (P > 0.05).Effects of dioscorin interventions on blood pressures of
HF diet-induced obese rats
Figure 2 showed the changes of SBP (Figure 2A) and
DBP (Figure 2B) in three rat groups after obesity-
induced stages (day 36 to day 70). From the results of
Figure 2A, the rats in the normal diet group showed
lower SBP and significant differences (P < 0.05) com-
pared to those in the HF diet group at 6-, 7-, 8-, and 9-
week. While, dioscorin intervention group (HF diet +
dio50) showed lower SBP and significant differences (P <
0.05) compared to those in the HF diet group at 7-, 8-,
and 9-week (corresponding to dioscorin intervention for
2 weeks, 3 weeks, and 4 weeks, respectively) and compar-
able to those in the normal diet group. From the results of
Figure 2B, the rats in the normal diet group showed lower
DBP and significant differences (P < 0.05) compared to
those in the HF diet group at 6-, 7-, 8-, and 9-week.
Dioscorin intervention group (HF diet + dio50) showed
lowered SBP, however, did not exhibit significant differ-
ences (P > 0.05) compared to those in the HF diet
group at 7-, 8-, and 9-week. These results showed that
the dioscorin intervention could improve blood pres-
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Figure 2 Effects of dioscorin interventions (50 mg/kg) on (A)
systolic blood pressure and (B) diastolic blood pressures of high
fat-diet induced obese rats. Blood pressure was measured at the end
of each week after dioscorin intervention for 1-, 2-, 3-, and 4-weeks by
using an indirect tail-cuff blood pressure meter (BP-98A, Softron Co.
Ltd. Tokyo, Japan). Data were expressed as mean ± SD. Multiple group
comparisons under the same treated time were performed using
one-way analysis of variance followed by the post hoc Tukey’s test, and
values that have not been indicated with the same alphabet were
significantly different (P< 0.05). HF, a high-fat diet; (HF diet + dio50), yam
dioscorin (50 mg/kg, dio50) was intervened daily concurrent HF diet.
Time (min)











































Figure 3 Effects of dioscorin interventions (50 mg/kg) on
impaired glucose intolerances of high fat-diet induced obese
rats by oral glucose tolerance tests. Data were expressed as
mean ± SEM. Multiple group comparisons under the same treated
time were performed using one-way analysis of variance followed
by the post hoc Tukey’s test, and values that have not been indicated
with the same alphabet were significantly different (P < 0.05). HF, a
high-fat diet; (HF diet + dio50), yam dioscorin (50 mg/kg, dio50) was
intervened daily concurrent HF diet.
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tolerances of HF diet-induced obese rats
After fasting overnight, the impaired glucose tolerance of
rats in three groups were measured by OGTT (Figure 3).
Plasma glucose concentrations (mg/dL) of the normal diet
group in the 0, 5, 30, 60, 90, and 120 min were 81.19 ±
6.09, 96.22 ± 18.67, 117.13 ± 15.22, 103.90 ± 5.22, 92.14 ±
7.57, and 87.24 ± 3.77, respectively; plasma glucose con-
centrations (mg/dL) of HF diet group were 95.40 ± 5.66,
101.67 ± 4.07, 113.39 ± 5.04, 111.75 ± 5.51, 105.48 ± 7.02,
and 108.05 ± 8.34, respectively; plasma glucose concentra-
tions (mg/dL) of (HF diet + dio50) group were 78.31 ±
6.66, 83.66 ± 3.06, 99.50 ± 8.42, 89.92 ± 6.08, 86.59 ± 7.52,
and 81.14 ± 7.21, respectively. At the beginning, rats in the
normal diet group and (HF diet + dio50) group showed
lower plasma glucose concentrations and significant differ-
ences (P < 0.05) compared to those in the HF diet group.
Later, rats in the (HF diet + dio50) group kept the lowest
plasma glucose concentrations and significant differences
(P < 0.05) among three rat groups at each 5-min, 30-min,60-min, 90-min, and 120-min time intervals and compar-
able to rats in the normal diet group at 90-min and 120-
min time intervals. The plasma glucose concentrations of
rats in the normal diet groups and (HF diet + dio50) group
were then back to the baseline at 120 min, however, the
plasma glucose concentrations of rats in the HF diet group
were still kept at higher levels (108.05 ± 8.34 mg/dL). From
the OGTT data, it meant that the dioscorin intervention
could improve impaired glucose tolerances of HF diet-
induced obese rats.
DPP IV inhibitory activities of peptic hydrolysates of yam
dioscorin
The reverse phase HPLC chromatograms of peptic hydro-
lysates of yam dioscorin with molecular mass between 3
kD and 10 kD (3 kD < peptide < 10 kD, Figure 4A) and less
than 3 kD (peptide < 3kD, Figure 4B) were shown at
Figure 4. These two hydrolytic fractions were used to
analyze the DPP IV inhibitory activities compared to the
positive control of sitagliptin phosphate (Figure 4C). The
sitagliptin phosphate showed dose-dependent inhibitions
against DPP IV. Under 5 mg/ml doses, the peptide frac-
tions of 3 kD < peptide < 10 kD and peptide < 3kD, re-
spectively, showed 80.82 ± 2.68 (%) and 54.42 ± 3.51 (%)
DPP IV inhibitory activities which might be equivalent to
sitagliptin phosphate of 250.86 nM and 61.79 nM,
respectively.
Discussion
The present animal experiments showed that the dios-
corin interventions at dose of 50 mg/kg daily for five
(A) (B)
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peptide < 3000 Da
Dioscorin hydrolysates
            (mg/ml)
(C)
Figure 4 DPP IV inhibitory activities of peptic hydrolysates of yam dioscorin. (A) HPLC chromatograms of yam dioscorin peptic
hydrolysates with molecular mass between 3 kD and 10 kD, (B) HPLC chromatograms of yam dioscorin peptic hydrolysates with molecular mass
less than 3 kD, and (C) DPP IV inhibitory activities of two fractions (5 mg/ml) of dioscorin peptic hydrolysates from molecular cut-off membrane
devices, and sitagliptin phosphate was acted as positive controls.
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ances, but had no effects on reductions of body weight
and fat tissues, of 10-week HF diet-induced obese rats
which the improved metabolic risks were involved in
MS criteria. The dioscorin and its peptic hydrolysates at
doses of 40 mg/kg were showed to have antihypertensive
activities against spontaneously hypertensive rats (SHR)
(Lin et al. 2006); the dioscorin at doses of 20 mg/kg or
80 mg/kg showed to lower oxidative stress of BALB/c
mice induced by subcutaneous galactose injections (Han
et al. 2014b). The obesity may play the central role in
MS which the renin-angiotensin system in dysfunctional
adipocytes will initiate inflammation and dyslipidemia,increase blood pressure and decrease insulin sensitivity
accompanied with abnormal blood glucose (Frigolet
et al. 2013). Therefore, anti-obesity or prevention against
obesity may reduce directly the risks of MS. There were
several reports concerning anti-obesity activity from nat-
ural resources in rodent models induced by HF diets,
such as α-lipoic acid (Kim et al. 2004), cryptotanshinone
from Salvia militorrhiza (Kim et al. 2007), rutin and o-
coumaric acid (Hsu et al. 2009), honokiol and magnolol
(Kim et al. 2013), pectin pentaoligosaccharide (Li et al.
2013), high taurine and glycine contents of scallop pro-
tein (Tastesen et al. 2014). The above-mentioned models
for HF diet-induced obese studies were generally applied
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then tested sample interventions or co-treatment of HF-
diet and tested samples in the same time. The vasorelaxing
peptides of Arg-Phe and Ile-His-Arg-Phe derived from
rice glutelin protein showed to lower food intakes in ro-
dent models (Kagebayashi et al. 2012; Kontani et al. 2014)
which maybe have anti-obesity activity. At present, it is
not sure that less amounts of dioscorin used with the simi-
lar MS preventive activities, or higher amounts of dios-
corin used or co-treatments of HF-diet and dioscorin used
with anti-obesity activities. Reagan-Shaw et al. (2007) sug-
gested to use body surface area normalization for dose
translation from animal to human studies. It was calcu-
lated that the human equivalent dose was 8.11 mg/kg of
human body weight from dioscorin intervention of
50 mg/kg of rat body weight in the present experiment.
An adult of 60 kg weigh might have to consume about
490 mg dioscorin/day to achieve benefits of improving MS
and need further investigations.
The yam dioscorin and its peptic hydrolysates or syn-
thesized peptides derived from dioscorin had been re-
ported to lower blood pressures using SHR as animal
models (Lin et al. 2006; Liu et al. 2009a,b; Lin et al.
2014). From the present results of Figure 2, dioscorin
intervention at least for two weeks showed to lower SBP
of HF diet-induced obese rats and comparable to the
normal diet fed ones. The dysfunctional adipocytes in
obesity will increase circulating renin-angiotensin sys-
tems, and the generated angiotensin II from angiotensin
I by angiotensin converting enzyme (ACE) hydrolysis re-
sulted in the higher blood pressures (Frigolet et al.
2013). It was reported that obesity may elevate systemic
oxidative stress from overloaded nutrients of HF diets
and advanced glycation endproduct generations (Kahn
et al. 2006). Glycation is the non-enzymatic modification
of proteins through the reduction of sugars and their
metabolized intermediates, such as glyoxal or methyl-
glyoxal, and leads to the irreversible formation of ad-
vanced glycation end products (Kikuchi et al. 2003). The
hypertensive rat might increase oxidative stress and
methylglyoxal amounts in vascular smooth muscle cells
(Wu and Juurlink 2002). The peptic hydrolysates of dios-
corin showed ACE inhibitory activities (Hsu et al. 2002)
and the synthesized peptides derived from pepsin hydro-
lysates in silico vasorelaxing activities (Lin et al. 2014).
The synthesized peptides derived from pepsin hydroly-
sates in silico exhibited antioxidant and antiglycation ac-
tivities in vitro and in vivo (Han et al. 2013; Han et al.
2014a,c). It was proposed that the dioscorin intervention
showed to lower SBP of HF diet-induced obese rats
might be from ACE inhibitory and vasorelaxing activ-
ities, and in part from antioxidant and/or antiglycation
activities of active peptides after dioscorin ingestions and
need further investigations.From the results of Figure 3, it was found that the im-
paired glucose tolerances in HF diet-induced obese rats
were improved after dioscorin interventions by OGTT
methods. At the beginning and the end of OGTT test,
the obese rats exhibited significantly higher glucose
levels compared to rats in normal diet group and (HF +
dio50) group. From the results of Figure 4, it was found
that yam dioscorin peptic hydrolysates with molecular
mass 3 kD < peptide < 10 kD and less than 3 kD at doses
of 5 mg/ml showed DPP IV inhibitory activities in vitro
which might be equivalent to effects of 250.86 nM and
61.79 nM of sitagliptin phosphate, respectively. More-
over, the undigested dioscorin was also used to evaluate
DPP IV inhibitory activity, under 5 mg/ml concentra-
tion, which showed 40.7% DPP IV inhibition (data not
show). The native dioscorin showed less anti-DPP IV ac-
tivity compared to the 3 kD < peptide < 10 kD and less
than 3 kD of dioscorin peptic hydrolysates. The results
of DPP IV activity of the native and digested dioscorin is
in agreement with the general observation that short-
chain biologically active peptides can be released and
absorbed in the small intestine after oral administration
(Phelan et al. 2009) which may correlate with the im-
proved OGTT. The sitagliptin phosphate, DPP IV inhibi-
tor approved by US FDA in 2006, can prolong GLP-1
biological activities to stimulate glucose-dependent insulin
secretions and for type 2 DM treatment in vivo (Idris and
Donnelly 2007; Drucker et al. 2007). The DPP IV inhibitor
(valine-pyrrolidide) showed the improved glucose toler-
ance and insulin secretion in HF diet-fed C57BL/6 J mice
(Ahrén et al. 2000). The mice fed a HF diet (58% fat) to-
gether with DPP IV inhibitor (NVP DPP728) in the drink-
ing water for 8 weeks showed the improved glucose
tolerance and increased circulating levels of insulin and
GLP-1 compared to HF diet only (Reimer et al. 2002). It
was suggested that the improved glucose tolerance in HF
diet-induced obese rats after dioscorin interventions might
be in part from DPP IV inhibitory activities of active pep-
tides from dioscorin after being ingested and need further
investigations.
Conclusions
In conclusion, yam dioscorin interventions exhibit the
improved MS activities in obese rats and peptic hydroly-
sates of yam dioscorin in vitro exhibit DPP IV inhibitory
activities which the related mechanisms may need fur-
ther investigations.
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